Prof. PeptideProf. Peptide

Phosphatidylserine

Cognitive & Nootropic

Last reviewed: May 26, 2026

Also Known As: PS, Sharp-PS (sunflower-derived ingredient form), phosphatidyl serine, soy-PS

Supplement Class: Phospholipid / neuronal membrane structural component / HPA-axis modulator

Evidence Tier: Strong — FDA qualified health claim for dementia and cognitive dysfunction risk reduction in elderly; Crook et al. 1991 + Cenacchi et al. 1993 multicenter trials (n=494 combined) for cognitive decline; Starks et al. 2008 documented cortisol blunting in exercise; Hirayama et al. 2014 pediatric ADHD trial; one of the few supplements at the FDA qualified-claim regulatory tier.

Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

What is phosphatidylserine?

Phosphatidylserine (PS) is a phospholipid — a fat-soluble molecule that forms a structural component of neuronal cell membranes. It is particularly concentrated in the brain, comprising roughly 15% of total neural-tissue phospholipid content. PS is reported to support neuronal membrane fluidity, facilitate synaptic neurotransmitter release, modulate HPA-axis cortisol response under stress, and participate in apoptosis signaling. Its supplement evidence base is notable in regulatory terms: PS is one of the few supplements to have earned an FDA qualified health claim for reducing the risk of dementia and cognitive dysfunction in the elderly — a higher regulatory tier than typical supplement marketing claims, though the FDA's own qualifier describes the underlying evidence as "very limited and preliminary." The cognitive evidence (Crook et al. 1991, Cenacchi et al. 1993 multicenter trials, n=494 combined) is strongest in age-related cognitive decline; the cortisol-blunting effect (Starks et al. 2008, roughly 20% post-exercise cortisol reduction at 600 mg) is documented in exercise contexts; pediatric ADHD evidence is emerging. PS is discussed alongside cognitive peptides like Semax and Selank because the membrane-structural and HPA-axis mechanisms operate on a different layer than receptor-level peptide signaling.

Reported benefits:

  • FDA qualified health claim for dementia and cognitive dysfunction risk reduction in the elderly
  • Memory and cognitive function improvements in age-related decline (Crook et al. 1991, Cenacchi et al. 1993)
  • Roughly 20% post-exercise cortisol blunting at 600 mg pre-stress (Starks et al. 2008)
  • Pediatric ADHD symptom improvement at 200 mg/day (Hirayama et al. 2014)
  • Neuronal membrane fluidity and integrity support (~15% of brain phospholipid)
  • Facilitated release of acetylcholine, dopamine, norepinephrine, and serotonin at synapses
  • HPA-axis modulation reducing ACTH and cortisol output under stress

Common dose: 100–300 mg/day total (often split 100 mg three times daily with meals) for cognitive support, per the Crook/Cenacchi trial range. 400–800 mg taken 30–60 minutes before a stressor for acute cortisol blunting, per the Starks et al. 2008 protocol. Dosing with fat-containing meals is the common label pattern, since PS absorption is fat-dependent.

Product-quality notes: Available over-the-counter as sunflower-derived or soy-derived softgels. Quality is reported to vary, particularly around dose disclosure — labels vary in whether they specify actual PS mg versus an undifferentiated "PS complex" figure. Review the quality-markers checklist in the Product-quality considerations section below.

On this page
  1. 1.How does phosphatidylserine work?
  2. 2.What does the evidence say phosphatidylserine does?
  3. 3.How is phosphatidylserine dosed in trials and on labels?
  4. 4.How phosphatidylserine is taken
  5. 5.What does phosphatidylserine stack with?
  6. 6.Side effects and interactions
  7. 7.What isn't established about phosphatidylserine
  8. 8.Product-quality considerations
  9. 9.Phosphatidylserine FAQ
  10. 10.References
  11. 11.Published Studies

How does phosphatidylserine work?

Phosphatidylserine works at the neuronal membrane structural layer — it is a major phospholipid component of brain cell membranes (roughly 15% of total brain phospholipid content). Supplementation is reported to support membrane fluidity, facilitate neurotransmitter release at synaptic terminals, and modulate HPA-axis cortisol response. The mechanism is structural rather than receptor-level signaling, which the literature cites as the reason cognitive effects build over weeks rather than appearing acutely — the exception is the cortisol-blunting arm, which is acute and dose-coupled to the stressor.

  1. Neuronal membrane structural support. PS is one of the four major phospholipids of brain cell membranes (alongside phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin). It maintains membrane fluidity — reported as essential for membrane protein function, receptor activity, ion channel behavior, and signal transduction. Age-related PS decline is reported to correlate with reduced cognitive function.
  2. Neurotransmitter release facilitation. PS is reported to support the membrane fusion events required for synaptic vesicle exocytosis — the release of acetylcholine, dopamine, norepinephrine, and serotonin at synaptic terminals.
  3. Cortisol blunting via HPA-axis modulation. PS is reported to inhibit hypothalamic-pituitary-adrenal axis activation in response to physical and psychological stress, reducing ACTH release and downstream cortisol output. Starks et al. 2008 reports roughly 20% post-exercise cortisol reduction with 600 mg PS — one of the more clearly documented physiological effects of PS supplementation.
  4. Apoptosis regulation. PS plays a role in phospholipid-dependent cell signaling and the regulation of programmed cell death. When cells signal for apoptosis, PS flips from the inner to the outer membrane leaflet — a recognition signal for clearance by macrophages, fundamental to neuronal turnover and brain homeostasis.
  5. Myelin sheath support. PS is incorporated into myelin — the lipid sheath around axons that enables fast nerve conduction. Adequate PS is reported to support myelin integrity, contributing to processing speed and cognitive efficiency.

What does the evidence say phosphatidylserine does?

PS has one of the more substantial cognitive-supplement evidence bases — substantial enough to earn an FDA qualified health claim for dementia and cognitive dysfunction risk reduction in the elderly. The strongest evidence is in age-related cognitive decline; the cortisol-blunting effect is documented in exercise contexts; the ADHD evidence is emerging; healthy-younger-adult cognitive evidence is weaker.

  1. Age-related cognitive decline (Strong). Crook et al. 1991 (n=149) reports significant memory improvements with 300 mg/day for 12 weeks. Cenacchi et al. 1993 (n=494) reports the cognitive benefit replicated in elderly populations over 6 months. These trials underpin the FDA qualified health claim.
  2. FDA qualified health claim (Regulatory). The FDA permits two qualified claims for PS: dementia risk reduction and cognitive dysfunction risk reduction in the elderly, both qualified as "scientific evidence very limited and preliminary." This regulatory tier sits between unsupported marketing claims and unqualified health claims; PS is one of the few supplements to hold it.
  3. Cortisol blunting in exercise stress (Strong). Starks et al. 2008 (n=10 endurance athletes) reports roughly 20% post-exercise cortisol reduction with 600 mg PS, replicated in several smaller athletic trials described in the literature. This is one of the more clearly documented physiological effects of PS supplementation.
  4. ADHD symptoms in children (Moderate). Hirayama et al. 2014 (n=36 pediatric ADHD) reports significant improvements in inattention, short-term auditory memory, and impulsivity at 200 mg/day for 2 months.
  5. General stress and HPA-axis dysfunction (Moderate). PS is reported to reduce psychological-stress-induced cortisol elevation in several smaller trials cited in the broader literature, with discussed applications spanning chronic stress, sleep disruption from elevated cortisol, and training overreaching.
  6. Healthy young-adult cognition (Weak). Trial evidence in healthy adults under 40 is reported as sparse, with smaller effect sizes than in populations with baseline cognitive decline.

How is phosphatidylserine dosed in trials and on labels?

PS dosing reported across trials differs by goal. Cognitive-support trials used 100–300 mg/day total; the acute cortisol-blunting trial used 400–800 mg taken 30–60 minutes before the stressor. Labels commonly specify dosing with fat-containing meals, since PS is fat-soluble and absorption is reported as meaningfully fat-dependent.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

  1. Cognitive support / age-related decline. 300 mg/day total, often split as 100 mg three times daily with meals — the Crook et al. 1991 and Cenacchi et al. 1993 trial dose.
  2. Cortisol blunting (acute, pre-stress). 400–800 mg taken 30–60 minutes before intense training or a high-stress event, per the Starks et al. 2008 protocol. The trial dosed before the stressor rather than on a chronic schedule.
  3. Chronic stress / HPA-axis support. 100–300 mg/day, split AM/PM, reflecting a lower-dose pattern discussed in chronic-use contexts of the broader literature.
  4. Pediatric ADHD adjunct. 200 mg/day, the Hirayama et al. 2014 trial dose, used under specialist supervision as an adjunct rather than a substitute for established ADHD treatment.

Reported timeline: cognitive effects emerge over 4–8 weeks of consistent use in the cited trials, with the FDA qualified-claim trial base built on 12-week to 6-month protocols. The cortisol-blunting effect is acute, within 30–60 minutes of dosing per the Starks trial protocol.

Label math. A "phosphatidylserine complex 500 mg" product may contain only 100 mg of actual PS, with the remainder being the broader phospholipid matrix. Labels vary in whether they disclose "PS" or "phosphatidylserine" content explicitly per serving. Most reported benefit plateaus above roughly 600 mg/day total.

How phosphatidylserine is taken

PS is taken orally, typically as softgels in an oil base or as capsules. The table below reports what trials and labels describe for timing, form, and standardization — source choice (soy vs. sunflower) is a secondary consideration.

AspectReported
FrequencyThree times daily (100 mg each) in the cognitive-use trial protocol; once pre-stress for cortisol blunting per Starks et al. 2008; an AM/PM split appears in discussions of general HPA-axis support.
Time of dayCognitive-use protocols dosed with meals throughout the day. The cortisol-blunting protocol dosed 30–60 minutes before intense training or a high-stress event. Some users report insomnia at high evening doses (uncommon but described in the literature).
FoodWith fat-containing meals — PS is fat-soluble and absorption is reported as meaningfully fat-dependent. Empty-stomach dosing is reported to reduce effective absorption.
FormSoftgels in an oil base are reported to have the best absorption; standard capsules are also used; powder is uncommon. Sunflower-derived PS is used by soy-sensitive users; soy-derived is reported as bioequivalent and typically cheaper.
Standardization markerLabels vary in whether "phosphatidylserine" mg per serving is explicitly disclosed versus an undifferentiated "phosphatidylserine complex" mass. The sunflower-derived ingredient form marketed as Sharp-PS is one quality-trademarked source used in trials; reputable soy-derived PS is reported as functionally equivalent. Bovine-derived PS is no longer marketed due to BSE concerns.
CyclingNo cycling protocol appears in the cognitive-use trials — chronic daily use is what was evaluated. The cortisol-blunting protocol is naturally pulsatile, dosed only around high-stress events.

What does phosphatidylserine stack with?

PS appears in the literature alongside the broader cognitive and stress-modulation toolkit. Its membrane-structural and HPA-axis mechanisms are discussed as complementary to neurotransmitter substrates, neurotrophic stimulators, and adaptogenic stress modulators.

With peptides

PS is discussed alongside the Russian-origin cognitive peptide cluster. Semax (an ACTH(4-10) analog) is reported to modulate BDNF and neurotrophic signaling. Selank (a tuftsin analog) is reported to provide anxiolytic and mild nootropic effects via GABA modulation. PS operates at a different layer — the structural neuronal membrane phospholipid, supporting membrane fluidity, synaptic neurotransmitter release, and HPA-axis cortisol modulation. No negative interaction is documented in the sources reviewed for this page.

With supplements

  1. Alpha-GPC — an acetylcholine substrate; PS supports the membrane environment while Alpha-GPC supplies the cholinergic substrate, a commonly discussed cognitive pairing.
  2. Bacopa monnieri — reported to work via chronic synaptic remodeling and memory consolidation on a different timescale (8–12 weeks) than PS's membrane-structural arm.
  3. Lion's Mane — NGF/BDNF stimulation, discussed as complementary to PS's membrane-structural and cortisol arms.
  4. Omega-3 fish oil — EPA/DHA are essential phospholipid fatty-acid components incorporated alongside PS into neuronal membranes, a mechanistically related pairing.
  5. Ashwagandha — an adaptogenic cortisol-modulating supplement at a different mechanism layer, discussed alongside PS's acute cortisol-modulation arm for chronic stress contexts.

With lifestyle factors

  1. Fat-containing meals. PS absorption is fat-dependent, per the mechanism above; labels commonly specify dosing alongside breakfast, lunch, or dinner.
  2. Pre-training cortisol-blunting timing. The Starks et al. 2008 protocol used 400–800 mg 30–60 minutes before high-intensity training.
  3. High-stress work contexts. The literature discusses the acute cortisol-blunting effect as applying to psychological stress beyond exercise, though this application has a smaller trial base than the exercise-cortisol finding.
  4. Consistent cognitive-use timing. For cognitive support, the cited trials measured effects from daily consistency over weeks rather than time-of-day precision.

Side effects and interactions

PS shows a favorable safety profile at standard doses across the trials cited on this page. The main considerations reported are mild GI effects, blood-thinning effects relevant for anticoagulant users, and rare insomnia at high evening doses.

Common (mostly transient)

  1. Mild GI discomfort — reported occasionally, particularly on an empty stomach; food coadministration is the common mitigation described in the literature.
  2. Insomnia at high evening doses — reported as uncommon and dose-related (600 mg+ in the evening); morning/midday dosing is the common mitigation.
  3. No serious adverse events are documented at supplemental doses across the human trial base cited above.

Less common (watch-list)

  1. Mild blood-thinning effect — reported as relevant for anticoagulant users, a modest additive effect that is documented but rarely clinically significant.
  2. Soy allergy with soy-derived PS — sunflower-derived PS is the reported alternative.
  3. Headache — reported occasionally, generally mild and dose-related.

Drug and supplement interactions

  1. Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran). PS's mild blood-thinning effect is reported as a modest additive interaction; clinician coordination is standard guidance for chronic anticoagulation users.
  2. NSAIDs at high chronic doses — a similar mild additive bleeding-risk consideration is reported.
  3. Cholinergic medications (donepezil, rivastigmine — Alzheimer's drugs) — PS's support of cholinergic neurotransmission is reported as potentially additive; clinician coordination is standard guidance.
  4. Pregnancy — data are limited; avoiding mega-dose supplementation is the standard guidance in this context.

What isn't established about phosphatidylserine

PS has earned a regulatory tier (FDA qualified health claim) that few supplements achieve, but several open questions remain — particularly around healthy young-adult cognitive transfer, the modern soy/sunflower-derived form versus the original bovine-derived trial form, and the long-term high-dose safety horizon.

Healthy young-adult cognitive transfer. The strongest cognitive evidence (Crook et al. 1991, Cenacchi et al. 1993) is in elderly populations with age-related memory impairment. Reported effect sizes in healthy adults under 40 are smaller and less consistently positive — evidence in elderly populations doesn't automatically generalize.

Bovine-derived vs plant-derived equivalence. The original cognitive trials used bovine cortex-derived PS, no longer commercially available due to BSE concerns. Modern PS is soy or sunflower lecithin-derived. The active molecule is reported as the same, but the trial evidence base is built on the bovine source; whether soy/sunflower-derived produces fully equivalent cognitive effects is mechanistically plausible but not directly head-to-head RCT-tested.

Optimal dose-response curve. Reported benefit plateaus above roughly 600 mg/day total in the literature reviewed. The Crook/Cenacchi cognitive dose is 300 mg/day; the Starks cortisol-blunting dose is 600 mg pre-stress. Whether higher doses (800–1,200 mg) produce additional benefit isn't well-characterized by the trials cited.

Multi-year safety at supplemental doses. Trial data extends to 6 months at 300 mg/day. Multi-year use at higher doses (600 mg+/day) isn't characterized in controlled trials.

ADHD efficacy beyond Hirayama 2014. The Hirayama et al. 2014 pediatric ADHD trial is positive, but the replication base is thin. Whether PS is effective for adult ADHD is mechanistically plausible but not well-tested.

Cortisol-blunting beyond exercise. Starks et al. 2008 tested exercise stress specifically. PS's effect on cortisol from psychological stress (work stress, sleep deprivation, anxiety) is mechanistically plausible but has a smaller cited trial base, with effect sizes in non-exercise contexts less well quantified.

FDA qualified-claim caveat. The qualified health claim itself carries the FDA's own disclaimer that "scientific evidence is very limited and preliminary" — a higher evidence tier than typical supplement marketing but not full FDA endorsement.

Product-quality considerations

PS is available over-the-counter from supplement retailers. Quality is reported to vary, particularly around source (soy vs. sunflower), oil-base formulation, and dose disclosure.

Quality markers reported in the category

  • Phosphatidylserine mg per serving explicitly disclosed — rather than an undifferentiated "phosphatidylserine complex" mass. Products commonly list 100–300 mg actual PS per capsule.
  • Sunflower-derived (marketed as Sharp-PS) or reputable soy-derived — both reported as bioequivalent; sunflower is the alternative for soy-sensitive users.
  • Softgels in an oil base — reported to have meaningfully better absorption than dry capsules for fat-soluble PS.
  • Third-party testing — USP, NSF, or ConsumerLab certifications signal independent verification.
  • cGMP-certified manufacturing facility.
  • Bovine-derived PS is no longer marketed in reputable channels due to BSE concerns from the 1990s.
  • Proprietary cognitive blends that combine PS with other ingredients without disclosing the actual PS dose don't allow independent evaluation of PS's contribution.
  • Fresh manufacture date — phospholipids are reported to degrade with prolonged storage.
Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

Phosphatidylserine FAQ

What does the FDA qualified health claim for PS mean?

The FDA permits two qualified health claims for phosphatidylserine: "Consumption of phosphatidylserine may reduce the risk of dementia in the elderly" and "Consumption of phosphatidylserine may reduce the risk of cognitive dysfunction in the elderly" — both carrying the FDA's qualifier that scientific evidence is "very limited and preliminary." The qualified health claim tier is rarer for supplements than unqualified claims, and PS is one of the few supplements to have earned it. The FDA's own framing places this above typical supplement marketing but well short of drug-level endorsement.

Does the source (sunflower vs soy-derived) affect PS's activity?

The active molecule is reported as identical regardless of plant source — soy lecithin-derived and sunflower lecithin-derived PS are described as bioequivalent. Reasons cited for choosing between them include soy allergy (sunflower-derived avoids this), general soy-avoidance preference, or cost (soy-derived is typically cheaper). Most of the trials cited on this page (Crook et al. 1991, the Cenacchi trials, the Starks 2008 sport-cortisol study) used soy-derived PS. Bovine brain-derived PS, used in some early European trials, is no longer commercially available following BSE (mad cow disease) concerns from the 1990s.

What does the cortisol-blunting evidence show?

Phosphatidylserine is reported to inhibit ACTH-mediated cortisol release after acute stress, including intense exercise. The Starks et al. 2008 crossover trial documented 600 mg PS reducing post-exercise cortisol by roughly 20% versus placebo following high-intensity cycling, with a concomitant ACTH reduction. This effect is described as acute and dose-coupled to the stressor rather than a chronic baseline shift — the trial dosed participants before the exercise stressor, not on a standing daily schedule.

Does PS improve memory in healthy adults?

The trial evidence is strongest in older adults with age-associated memory decline and thinner in healthy younger adults. Crook et al. 1991 (300 mg/day, 12 weeks) reports significant memory improvements in an elderly population with age-associated memory impairment; the Cenacchi trials (n=494 across the cited studies) report similar effects. Trial evidence in healthy younger adults is described as sparse, with smaller reported effect sizes.

Does PS stack with Semax or Selank?

The mechanisms are reported as complementary and addressing different layers of cognitive function. Semax (an ACTH(4-10) analog) is reported to modulate BDNF and neurotrophic signaling. Selank (a tuftsin analog) is reported to provide anxiolytic effects via GABA modulation. Phosphatidylserine operates at a structural layer — it is a major neuronal membrane phospholipid (roughly 15% of brain phospholipid content), and supplementation is reported to support membrane fluidity, neurotransmitter release, and cortisol regulation. No negative interaction between these is documented in the sources reviewed for this page.

How does PS compare mechanistically to Alpha-GPC and other cognitive supplements?

The mechanisms are distinct, and the compounds are often discussed together in stacking literature. Alpha-GPC is an acetylcholine substrate, with evidence in dementia contexts and acute exercise-related GH response. Bacopa monnieri is reported to work through chronic synaptic remodeling, with trial evidence measured over 8–12 weeks in healthy-adult memory retention. PS operates at the neuronal membrane layer — structural phospholipid support, neurotransmitter release facilitation, and cortisol blunting, per the mechanism section above. PS's cortisol arm is not shared by the acetylcholine-substrate or synaptic-remodeling supplements.

What doses appear in the cortisol-blunting vs cognitive-support trials?

The trials cited on this page used different dose protocols for the two use cases. Crook et al. 1991's cognitive-support trial used 100–300 mg/day total, often described as split into 100 mg three times daily with meals. The Starks et al. 2008 cortisol-blunting trial used 600 mg taken 30–60 minutes before the exercise stressor. A general HPA-axis-support pattern discussed in related literature runs 100–200 mg/day. Doses above 800 mg/day are reported to occasionally cause insomnia or GI upset in some users, and most reported benefit is described as plateauing above roughly 600 mg/day total.

What does the evidence say about long-term PS use?

Trial evidence extends to 6+ months at 300 mg/day with no reported concerning safety signal. Multi-year daily use has not been directly characterized by RCT, though the shorter-term safety profile is reported as reassuring. PS carries mild blood-thinning effects reported in the literature, which are relevant for people on anticoagulants (warfarin, apixaban, rivaroxaban) or high-dose NSAIDs — coordination with a prescribing clinician is the standard guidance for chronic anticoagulation users. Pregnancy safety data is insufficient; avoiding mega-dose supplementation in that context is the standard guidance.

References

  1. Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology. 1991;41(5):644-649. https://pubmed.ncbi.nlm.nih.gov/2027477/
  2. Cenacchi T, Bertoldin T, Farina C, et al. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano). 1993;5(2):123-133. https://pubmed.ncbi.nlm.nih.gov/8323999/
  3. Starks MA, Starks SL, Kingsley M, Purpura M, Jäger R. The effects of phosphatidylserine on endocrine response to moderate intensity exercise. J Int Soc Sports Nutr. 2008;5:11. https://pubmed.ncbi.nlm.nih.gov/18662395/
  4. Glade MJ, Smith K. Phosphatidylserine and the human brain. Nutrition. 2015;31(6):781-786. https://pubmed.ncbi.nlm.nih.gov/25933483/
  5. Hirayama S, Terasawa K, Rabeler R, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. J Hum Nutr Diet. 2014;27 Suppl 2:284-291. https://pubmed.ncbi.nlm.nih.gov/23495677/
  6. U.S. Food and Drug Administration. Qualified health claim: phosphatidylserine and cognitive dysfunction and dementia (Letter of Enforcement Discretion). 2003. https://www.fda.gov/food/qualified-health-claims/qualified-health-claims-letters-enforcement-discretion

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Neurology · 1991Paywalled
Effects of Phosphatidylserine in Age-Associated Memory Impairment →

Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC

A 12-week randomized double-blind placebo-controlled trial of 300 mg/day bovine cortex-derived PS in 149 patients with age-associated memory impairment. Reports significant improvements in name-face recall, telephone-number recall, and other memory-task performance versus placebo. This trial underpins the FDA's qualified health claim on dementia risk reduction. (Bovine-derived PS used in this trial is no longer marketed; modern soy/sunflower-derived PS is reported as functionally equivalent.)

Aging Clinical and Experimental Research · 1993Paywalled
Cognitive Decline in the Elderly: A Double-Blind, Placebo-Controlled Multicenter Study on Efficacy of Phosphatidylserine Administration →

Cenacchi T, Bertoldin T, Farina C, et al.

A 6-month multicenter RCT of 300 mg/day PS in 494 elderly Italian patients with cognitive decline. Reports significant improvement in cognitive function and behavioral parameters versus placebo across multiple assessment instruments — the largest single PS cognitive study and a key part of the evidence base supporting the FDA qualified health claim.

Journal of the International Society of Sports Nutrition · 2008Open Access
The Effects of Phosphatidylserine on Endocrine Response to Moderate Intensity Exercise →

Starks MA, Starks SL, Kingsley M, Purpura M, Jäger R

A crossover RCT in 10 endurance-trained athletes evaluating 600 mg/day soy-derived PS versus placebo for 10 days, with cortisol response measured after intensive cycling exercise. Reports PS significantly blunted post-exercise cortisol release by roughly 20% versus placebo, with a concomitant ACTH reduction — establishing PS's acute cortisol-blunting effect and the 600 mg pre-stress dose protocol.

Nutrition · 2015Paywalled
Phosphatidylserine and the Human Brain →

Glade MJ, Smith K

A review of PS biology and supplementation evidence covering neuronal membrane biology, cognitive trials in age-related decline, the FDA qualified health claim regulatory pathway, cortisol modulation, and exercise applications.

Journal of Human Nutrition and Dietetics · 2014Open Access
The Effect of Phosphatidylserine Administration on Memory and Symptoms of Attention-Deficit Hyperactivity Disorder →

Hirayama S, Terasawa K, Rabeler R, et al.

A randomized double-blind placebo-controlled trial of 200 mg/day soy-derived PS in 36 children with ADHD over 2 months. Reports significant improvements in ADHD symptoms, inattention, short-term auditory memory, and impulsivity versus placebo.

PhospholipidMemoryCortisol BluntingFDA Qualified ClaimNeuronal MembraneHPA-Axis

Related Supplements

Alpha-GPCBacopa MonnieriLion's ManeFish OilAshwagandha

We may earn commissions from peptide vendor affiliate links.

Have a question about Phosphatidylserine? Send us an email